Roche has revealed that Rituxan (rituximab), also known as MabThera, has been awarded US approval from the FDA in combination with glucocorticoids for the treatment of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MA) in children over the age of two years old.
The two conditions are forms of ANCA-associated vasculitis, broadly affecting the small blood vessels of the kidneys, lungs, and sinuses, among other areas. The approval marks the first for the drug in a paediatric indication.
